Nothing out of the ordinary will take place as is stated and reaffirmed in the announcement. Only the business outlined in the notice is on the agenda. Do not expect anything to transpire beyond what is already public information.
I realize that this is SPAM. Having said that, I would like to mention that CNBC is comprised of the most idiots and clueless individuals imaginable. I would not listen to their advice and feel comfortable doing the opposite of what they usually recommend. Recently they huge were Perma Bears predicting that the sky was falling and this resulted in a monstrous market turnaround.
Jim Cramer is a nut.
In order for a generic drug manufacturer to win approval of a drug under the Hatch-Waxman Act, the generic manufacturer must certify that they will not launch their generic until after the expiration of the Orange Book-listed patent, or that the patent is invalid, unenforceable, or that the generic product will not infringe the listed patent.
Drug-Makers on Vanguard Level- Biodel (NASDAQ:BIOD), Pernix Therapeutics (NASDAQ:PTX)
Thursday bloom on Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) [Trend Analysis], stock build up around 4.36% in early session as its gaining volume of 27.11 Million. Pernix Therapeutics Holdings, Inc. (PTX) released that U.S. Patent and Trademark Office has issued U.S. Patent Numbers 9,339,499 (‘499 patent), 9,326,982, and 9,333,201 (‘201 patent), covering important safety information related to dosing patients with Zohydro ER with BeadTek.
These patents, in addition to the 9,265,760 patent (‘760 patent) which issued February 23, 2016, are broadly directed to a method of dosing patients with hepatic impairment with hydrocodone where no adjustment in start dose is needed for patients with mild or moderate hepatic impairment. The ‘760, ‘499, ‘982 and ‘201 patents expire July 25, 2033.
“The ‘499, ‘982, and the ‘201 patents, solely owned by Pernix, are a significant addition to the Orange Book, bringing the total number of Orange Book listed patents covering Zohydro ER with BeadTek to seven,” said John Sedor, Chairman and Interim CEO of Pernix Therapeutics. “We continue to invest in this brand and currently have a half dozen more patent applications pending relating to Zohydro ER with BeadTek.”
A buyout or merger is possible and would require an acquiring company with adequate cash to purchase the drugs in exchange for paying the debt and compensating the stockholders with stock of the suitor company.
Longs will be issued a debit card in the amount of shares they hold which can be used at any company store.